Scholarlink

Introduction <p>Although gonadotropin-releasing hormone analogs (GnRHa) are the standard treatment for central precocious puberty (CPP), the efficacy of GnRHa monotherapy in older children (around 8&#xa0;years) and that of combination therapy with recombinant human growth hormone (rhGH) both remain unclear. This study aims to evaluate the real-world efficacy of each regimen.</p> Methods <p>This retrospective cohort study enrolled Chinese girls with CPP. Two groups were formed: GnRHa monotherapy and GnRHa + rhGH combination therapy. Outcomes included adult height gain [AHG, final adult height (FAH) standard deviation score (SDS)– predicted adult height (PAH) SDS]，genetic height gain [GHG, FAH SDS–target height (Tht) SDS], and change in height (FAH SDS&#xa0;–&#xa0;baseline height SDS).</p> Results <p>In the GnRHa group, the mean age at treatment initiation was 8.87 ± 0.87&#xa0;years. After 17.87&#xa0;months of treatment, the AHG was 1.33 SDS (0.82, 2.00). In the GnRHa + rhGH group, the mean age at treatment initiation was 9.01 ± 0.80&#xa0;years. After 23.02&#xa0;months of GnRHa treatment and 14.02&#xa0;months of rhGH treatment, the group showed significantly greater AHG [1.72 SDS (1.24, 2.59)].</p> Conclusions <p>GnRHa monotherapy initiated after age 8 may still provide meaningful height gains, and adding rhGH is associated with improved FAH in patients with severe baseline height impairment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Adult Height Outcomes in Girls with Central Precocious Puberty Receiving GnRHa Monotherapy or Combined with Growth Hormone: A Cohort Study in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Fei Wang,
  • Yan Li,
  • Yu Yang,
  • Wei Gu,
  • Xuan Xu,
  • Haiying Wu,
  • Guimei Li,
  • Xiaoqin Yin,
  • Shasha Zhou,
  • Pin Li

摘要

Introduction

Although gonadotropin-releasing hormone analogs (GnRHa) are the standard treatment for central precocious puberty (CPP), the efficacy of GnRHa monotherapy in older children (around 8 years) and that of combination therapy with recombinant human growth hormone (rhGH) both remain unclear. This study aims to evaluate the real-world efficacy of each regimen.

Methods

This retrospective cohort study enrolled Chinese girls with CPP. Two groups were formed: GnRHa monotherapy and GnRHa + rhGH combination therapy. Outcomes included adult height gain [AHG, final adult height (FAH) standard deviation score (SDS)– predicted adult height (PAH) SDS]，genetic height gain [GHG, FAH SDS–target height (Tht) SDS], and change in height (FAH SDS – baseline height SDS).

Results

In the GnRHa group, the mean age at treatment initiation was 8.87 ± 0.87 years. After 17.87 months of treatment, the AHG was 1.33 SDS (0.82, 2.00). In the GnRHa + rhGH group, the mean age at treatment initiation was 9.01 ± 0.80 years. After 23.02 months of GnRHa treatment and 14.02 months of rhGH treatment, the group showed significantly greater AHG [1.72 SDS (1.24, 2.59)].

Conclusions

GnRHa monotherapy initiated after age 8 may still provide meaningful height gains, and adding rhGH is associated with improved FAH in patients with severe baseline height impairment.